Covagen
Schlieren
About Covagen
Covagen develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy in the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architectures to maximize efficacy. Their goal is to access novel biology for each product candidate. Covagen’s lead FynomAb COVA322 is being developed for the treatment of inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis. In October 2012 Covagen entered into a strategic research collaboration and license agreement with Mitsubishi Tanabe / TRL for the development of bispecific FynomAbs against target pairs selected by Mitsubishi Tanabe / TRL. Covagen was founded in 2007 as a spin-off company from ETH Zurich (Swiss Federal Institute of Technology). A strong syndicate of investors supports Covagen’s drug development programs including Novartis Venture Fund, Edmond de Rothschild Investment Partners, Gimv, Seroba Kernel Life Sciences, Ventech, Ascent Biomedical Venture Management, MP Healthcare Venture Management, and Baxter Ventures.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $72.4M
- Funding stage: M&A
- Last round: Series B (Dec 2013)
- Website: covagen.com
- Phone: +41 0447-324-660
Industries & Categories
Biopharma, Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/covagen-2629276 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.